These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 34649106)

  • 1. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
    Popat S; Jung HA; Lee SY; Hochmair MJ; Lee SH; Escriu C; Lee MK; Migliorino MR; Lee YC; Girard N; Daoud H; Märten A; Miura S
    Lung Cancer; 2021 Dec; 162():9-15. PubMed ID: 34649106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential Afatinib and Osimertinib in Asian Patients with
    Miura S; Jung HA; Lee SY; Lee SH; Lee MK; Lee YC; Hochmair MJ; Yang CT; Märten A; Yang JC; Popat S
    Onco Targets Ther; 2022; 15():873-882. PubMed ID: 36033903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
    Yamamoto N; Mera T; Märten A; Hochmair MJ
    Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
    Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
    Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
    Popat S; Hsia TC; Hung JY; Jung HA; Shih JY; Park CK; Lee SH; Okamoto T; Ahn HK; Lee YC; Sato Y; Lee SS; Mascaux C; Daoud H; Märten A; Miura S
    Oncologist; 2022 Apr; 27(4):255-265. PubMed ID: 35274704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
    Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential afatinib and osimertinib in patients with
    Hochmair MJ; Morabito A; Hao D; Yang CT; Soo RA; Yang JC; Gucalp R; Halmos B; Wang L; Märten A; Cufer T
    Future Oncol; 2019 Sep; 15(25):2905-2914. PubMed ID: 31370698
    [No Abstract]   [Full Text] [Related]  

  • 8. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
    Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.
    Yang Y; Liu Q; Cao L; Sun W; Gu X; Liu B; Xiao N; Teng F; Li X; Chen M; Yu W; Lin H; Xu G
    BMC Pulm Med; 2021 May; 21(1):172. PubMed ID: 34011336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring
    Chen CH; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Anticancer Res; 2022 Apr; 42(4):2145-2157. PubMed ID: 35347039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S; Shih JY; Jang TW; Liam CK; Yu Y
    Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
    Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
    Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot DM; Tan EH; Tanaka H; Wu YL; Yang JC; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N
    Lung Cancer; 2019 Jun; 132():126-131. PubMed ID: 31097085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
    Hochmair MJ; Morabito A; Hao D; Yang CT; Soo RA; Yang JC; Gucalp R; Halmos B; Wang L; Golembesky A; Märten A; Cufer T
    Future Oncol; 2018 Nov; 14(27):2861-2874. PubMed ID: 30336693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib.
    Minari R; Leonetti A; Gnetti L; Zielli T; Ventura L; Bottarelli L; Lagrasta C; La Monica S; Petronini PG; Alfieri R; Tiseo M
    Anticancer Drugs; 2021 Aug; 32(7):758-762. PubMed ID: 33675607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
    Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
    Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A
    Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study.
    Kim T; Jang TW; Choi CM; Kim MH; Lee SY; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Oh HJ
    Cancer Res Treat; 2023 Oct; 55(4):1152-1170. PubMed ID: 37218139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.